These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 36634171)

  • 1. Alzheimer's drug approval gets a mixed reception.
    Couzin-Frankel J
    Science; 2023 Jan; 379(6628):126-127. PubMed ID: 36634171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A carte blanche approval in Alzheimer's.
    Nat Biotechnol; 2021 Jul; 39(7):781. PubMed ID: 34183862
    [No Abstract]   [Full Text] [Related]  

  • 3. FDA approves Alzheimer's drug lecanemab amid safety concerns.
    Reardon S
    Nature; 2023 Jan; 613(7943):227-228. PubMed ID: 36627422
    [No Abstract]   [Full Text] [Related]  

  • 4. US FDA defends approval of Alzheimer's disease drug.
    Jaffe S
    Lancet; 2021 Jul; 398(10294):12. PubMed ID: 34217382
    [No Abstract]   [Full Text] [Related]  

  • 5. A contentious FDA ruling for Alzheimer's disease.
    The Lancet Neurology
    Lancet Neurol; 2021 Aug; 20(8):585. PubMed ID: 34237273
    [No Abstract]   [Full Text] [Related]  

  • 6. Controversial Approval of New Drug to Treat Alzheimer's Disease.
    Aschenbrenner DS
    Am J Nurs; 2021 Oct; 121(10):22-23. PubMed ID: 34554982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aduhelm: The Best Hope for Alzheimer's Disease Patients or the Worst Decision the FDA Has Ever Made?
    Kurkinen M; Tran L
    J Alzheimers Dis; 2021; 84(3):969-971. PubMed ID: 34657888
    [No Abstract]   [Full Text] [Related]  

  • 8. Controversy and Progress in Alzheimer's Disease - FDA Approval of Aducanumab.
    Rabinovici GD
    N Engl J Med; 2021 Aug; 385(9):771-774. PubMed ID: 34320284
    [No Abstract]   [Full Text] [Related]  

  • 9. Landmark Alzheimer's drug approval confounds research community.
    Mullard A
    Nature; 2021 Jun; 594(7863):309-310. PubMed ID: 34103732
    [No Abstract]   [Full Text] [Related]  

  • 10. How the US Food and Drug Administration's approval of aducanumab for Alzheimer's disease has implication for oncology and beyond.
    Lythgoe MP; Prasad V
    Eur J Cancer; 2021 Nov; 157():68-70. PubMed ID: 34487987
    [No Abstract]   [Full Text] [Related]  

  • 11. [Aducanumab approval for Alzheimer's disease in the USA: the surrender of science].
    Dal-Ré R
    Rev Neurol; 2021 Oct; 73(8):296-297. PubMed ID: 34617583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Controversial Alzheimer's drug approval could affect other diseases.
    Mullard A
    Nature; 2021 Jul; 595(7866):162-163. PubMed ID: 34193994
    [No Abstract]   [Full Text] [Related]  

  • 13. FDA Drug Approval and the Ethics of Desperation.
    Largent EA; Peterson A; Lynch HF
    JAMA Intern Med; 2021 Dec; 181(12):1555-1556. PubMed ID: 34694325
    [No Abstract]   [Full Text] [Related]  

  • 14. The approval of Aduhelm risks eroding public trust in Alzheimer research and the FDA.
    Karlawish J; Grill JD
    Nat Rev Neurol; 2021 Sep; 17(9):523-524. PubMed ID: 34267383
    [No Abstract]   [Full Text] [Related]  

  • 15. Doubts persist for claimed Alzheimer's drug.
    Servick K
    Science; 2019 Dec; 366(6471):1298. PubMed ID: 31831649
    [No Abstract]   [Full Text] [Related]  

  • 16. Lecanemab Gains FDA Approval for Early Alzheimer Disease.
    Larkin HD
    JAMA; 2023 Feb; 329(5):363. PubMed ID: 36652625
    [No Abstract]   [Full Text] [Related]  

  • 17. Ignoring the Experts: Implications of the FDA's Aduhelm Approval.
    Maulden A
    Am J Law Med; 2022 Mar; 48(1):108-133. PubMed ID: 35815585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of Aducanumab for Alzheimer Disease: Scientific Evidence and Regulatory Review Involving Efficacy, Safety, and Futility.
    Alexander GC; Emerson S; Kesselheim AS
    JAMA; 2021 May; 325(17):1717-1718. PubMed ID: 33783469
    [No Abstract]   [Full Text] [Related]  

  • 19. Revisiting FDA Approval of Aducanumab.
    Alexander GC; Knopman DS; Emerson SS; Ovbiagele B; Kryscio RJ; Perlmutter JS; Kesselheim AS
    N Engl J Med; 2021 Aug; 385(9):769-771. PubMed ID: 34320282
    [No Abstract]   [Full Text] [Related]  

  • 20. The Current State of Pharma and the FDA: Approval of a Dementia Drug as a Case in Point.
    Eiser AR
    Am J Med; 2021 Dec; 134(12):1442-1443. PubMed ID: 34256026
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.